Literature DB >> 28967954

Deviation Management: Key Management Subsystem Driver of Knowledge-Based Continuous Improvement in the Henry Ford Production System.

Richard J Zarbo1, Jacqueline R Copeland1, Ruan C Varney1.   

Abstract

OBJECTIVES: To develop a business subsystem fulfilling International Organization for Standardization 15189 nonconformance management regulatory standard, facilitating employee engagement in problem identification and resolution to effect quality improvement and risk mitigation.
METHODS: From 2012 to 2016, the integrated laboratories of the Henry Ford Health System used a quality technical team to develop and improve a management subsystem designed to identify, track, trend, and summarize nonconformances based on frequency, risk, and root cause for elimination at the level of the work.
RESULTS: Programmatic improvements and training resulted in markedly increased documentation culminating in 71,641 deviations in 2016 classified by a taxonomy of 281 defect types into preanalytic (74.8%), analytic (23.6%), and postanalytic (1.6%) testing phases. The top 10 deviations accounted for 55,843 (78%) of the total.
CONCLUSIONS: Deviation management is a key subsystem of managers' standard work whereby knowledge of nonconformities assists in directing corrective actions and continuous improvements that promote consistent execution and higher levels of performance. © American Society for Clinical Pathology, 2017. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  Continuous improvement; Deviation management; Henry Ford Production System; ISO 15189; Lean

Mesh:

Year:  2017        PMID: 28967954     DOI: 10.1093/ajcp/aqx084

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  1 in total

Review 1.  Implementing a Quality Management System in the Medical Microbiology Laboratory.

Authors:  Roberta B Carey; Sanjib Bhattacharyya; Sue C Kehl; Larissa M Matukas; Michael A Pentella; Max Salfinger; Audrey N Schuetz
Journal:  Clin Microbiol Rev       Date:  2018-05-02       Impact factor: 26.132

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.